Treatment-Resistant Depression Treatment Market - Strategic Insights and Forecasts (2026-2031)

The Treatment-Resistant Depression Treatment Market is projected to grow from USD 3.794 billion in 2025 to USD 5.342 billion by 2031. This market is anticipated to expand at a Compound Annual Growth Rate (CAGR) of 5.87% throughout the forecast period, indicating a steady growth trajectory.

The market growth is primarily driven by the rising global prevalence of depression, with approximately 30% of the 280 million people suffering from depression having TRD. Additionally, increasing awareness about mental health outcomes, government initiatives, and research activities, coupled with the alarming rise in suicide rates linked to depression, are significant growth contributors.

North America is highlighted as the leading region in the Treatment-Resistant Depression Treatment Market. Its dominance is attributed to advanced healthcare infrastructure, robust research activities, and the early adoption of novel treatments like S-Ketamine, driving market expansion and innovation.

Treatment-Resistant Depression (TRD) is defined as a mental state condition where a person's depression does not improve after receiving at least two courses of medication. Novel treatments, such as S-Ketamine, are gaining approval and adoption, significantly influencing the market landscape by offering new therapeutic options for those who haven't responded to traditional antidepressants.

The Treatment-Resistant Depression Treatment Market is anticipated to grow at a steady pace throughout the forecast period (2026-2031). The increasing global prevalence of depression, growing public awareness, government initiatives, and continuous research into new treatment modalities are expected to sustain this positive market trajectory.

Significant demographic trends include the rising global cases of depression, affecting nearly 5% of adults, with approximately 30% of these cases being TRD. Notably, women are more prone to major depressive disorder and treatment-resistant disorder than men, with a ratio of 2.6 to 1, indicating a key demographic segment for treatment focus.